Principal Financial Group Inc. Decreases Stock Position in Ralliant Corporation $RAL

Principal Financial Group Inc. trimmed its holdings in Ralliant Corporation (NYSE:RAL) by 20.5% during the third quarter, Holdings Channel.com reports. The fund owned 540,932 shares of the company’s stock after selling 139,242 shares during the period. Principal Financial Group Inc.’s holdings in Ralliant were worth $23,655,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. UMB Bank n.a. purchased a new stake in shares of Ralliant in the third quarter valued at about $29,000. Thrivent Financial for Lutherans raised its position in shares of Ralliant by 60.5% during the 3rd quarter. Thrivent Financial for Lutherans now owns 210,045 shares of the company’s stock worth $9,185,000 after purchasing an additional 79,173 shares during the last quarter. Keybank National Association OH lifted its stake in Ralliant by 17.7% in the 3rd quarter. Keybank National Association OH now owns 19,362 shares of the company’s stock valued at $847,000 after buying an additional 2,910 shares in the last quarter. Welch & Forbes LLC purchased a new stake in Ralliant in the 3rd quarter valued at approximately $854,000. Finally, Arizona State Retirement System grew its holdings in Ralliant by 1.2% during the 3rd quarter. Arizona State Retirement System now owns 33,566 shares of the company’s stock valued at $1,468,000 after buying an additional 413 shares during the last quarter.

Ralliant Stock Up 2.9%

RAL opened at $39.50 on Friday. Ralliant Corporation has a 12 month low of $37.27 and a 12 month high of $57.02. The business has a 50-day moving average of $51.52 and a two-hundred day moving average of $46.72. The company has a debt-to-equity ratio of 0.38, a current ratio of 0.84 and a quick ratio of 1.03. The stock has a market capitalization of $4.46 billion and a price-to-earnings ratio of 31.10.

Ralliant (NYSE:RAL) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $0.69 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.02. The company had revenue of $554.60 million for the quarter, compared to analysts’ expectations of $543.04 million. The company’s quarterly revenue was up 1.2% on a year-over-year basis. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, March 23rd. Shareholders of record on Monday, March 9th will be issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Monday, March 9th. Ralliant’s dividend payout ratio (DPR) is 15.75%.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Barclays boosted their price target on Ralliant from $59.00 to $60.00 and gave the stock an “overweight” rating in a report on Wednesday, January 7th. Morgan Stanley restated an “overweight” rating and issued a $45.00 target price on shares of Ralliant in a report on Friday. Truist Financial decreased their price target on shares of Ralliant from $62.00 to $49.00 and set a “buy” rating on the stock in a research note on Friday. Weiss Ratings lowered shares of Ralliant from a “hold (c)” rating to a “sell (d)” rating in a research report on Thursday. Finally, Royal Bank Of Canada reduced their price objective on shares of Ralliant from $52.00 to $41.00 and set a “sector perform” rating on the stock in a research note on Friday. Seven analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Ralliant has a consensus rating of “Moderate Buy” and an average target price of $51.30.

Key Stories Impacting Ralliant

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Analyst upgrades: Vertical Research upgraded Ralliant from “hold” to “buy” with a $45 price target, which supports near‑term upside expectations. The Fly: Vertical Research upgrade
• Positive Sentiment: Citigroup maintained a “buy” rating (but trimmed its PT to $51 from $61), which still implies meaningful upside and likely helped calm some selling pressure. Benzinga: Citigroup note
• Positive Sentiment: Quarterly results modestly beat: Q4 EPS of $0.69 (vs. $0.67 est.) and revenue of ~$554.6M (vs. $543M est.), showing underlying operational resilience despite the one‑time items. MarketBeat: Q4 results
• Neutral Sentiment: Company set 2026 revenue target of $2.1B–$2.2B (roughly in line with consensus), which supports the topline outlook but is tempered by other items below. BusinessWire: FY2026 outlook
• Negative Sentiment: Material non‑cash charge: the company recorded a $1.4B goodwill impairment in its Test & Measurement segment (EA Elektro‑Automatik), producing a large reported net loss and triggering the recent sharp selloff. MarketWatch: $1.4B impairment
• Negative Sentiment: Multiple law‑firm investigations and investor notices (Holzer & Holzer, Johnson Fistel, Block & Leviton) are underway into the impairment and disclosures, adding legal/exec‑risk uncertainty. GlobeNewswire: Investor alerts
• Negative Sentiment: Shares recently hit an all‑time low after the impairment and heavy losses were disclosed, which can pressure sentiment until clarity on write‑ups, integration and legal outcomes emerges. InsiderMonkey: All‑time low coverage

Ralliant Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.